1. PW is a 68 yo male diagnosed with EGFR mutation-positive NSCLC (original tumor biopsy showed EGFR exon 21 L858R substitution) who has been treated with first-line EGFR TKI therapy for the past 12 months. PW recently started having severe back pain and workup reveals non-cord compression progression of disease in the T spine while on erlotinib therapy. What would be the MOST appropriate next step?

2. Which of the following is the most common EGFR acquired resistance mechanism in EGFR mutation-positive NSCLC?

3. Which of the following EGFR TKIs would you expect to have the lowest incidence of dermatologic (Grade 3/4) toxicities?

4. What percentage of oncology medication costs in 2015 were attributed to tyrosine kinase inhibitors (TKIs)?

« Return to Activity